• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Tuesday, February 7, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

StockNews.com Downgrades Blueprint Medicines (NASDAQ:BPMC) To Sell

by Duong
February 26, 2022
in Cambridge
stocknews.com-downgrades-blueprint-medicines-(nasdaq:bpmc)-to-sell
Share on FacebookShare on Twitter

Blueprint Medicines logoBlueprint Medicines (NASDAQ:BPMC – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms have also recently issued reports on BPMC. Morgan Stanley lowered their target price on Blueprint Medicines from $111.00 to $92.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 1st. Raymond James increased their target price on Blueprint Medicines from $122.00 to $133.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, November 10th. Stifel Nicolaus raised Blueprint Medicines from a “hold” rating to a “buy” rating and lowered their target price for the stock from $120.00 to $95.00 in a research note on Monday, January 24th. Guggenheim increased their target price on Blueprint Medicines from $120.00 to $122.00 in a research note on Monday, January 3rd. Finally, Zacks Investment Research cut Blueprint Medicines from a “hold” rating to a “sell” rating and set a $80.00 target price for the company. in a research note on Friday, January 14th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $109.82.

(Ad)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Shares of BPMC stock opened at $62.18 on Friday. The stock has a market cap of $3.68 billion, a PE ratio of -5.66 and a beta of 0.86. The stock has a 50-day moving average of $84.24 and a 200-day moving average of $94.99. Blueprint Medicines has a one year low of $60.53 and a one year high of $117.86.

Blueprint Medicines (NASDAQ:BPMC – Get Rating) last announced its quarterly earnings results on Tuesday, February 15th. The biotechnology company reported ($5.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($4.73). The company had revenue of $107.00 million during the quarter, compared to the consensus estimate of $104.14 million. Blueprint Medicines had a negative net margin of 357.66% and a negative return on equity of 28.96%. The business’s revenue was up 213.8% compared to the same quarter last year. During the same period last year, the company earned ($1.53) earnings per share. Analysts anticipate that Blueprint Medicines will post -6.82 EPS for the current year.

In other news, EVP Tracey L. Mccain sold 5,000 shares of the company’s stock in a transaction dated Tuesday, December 7th. The shares were sold at an average price of $97.30, for a total value of $486,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider L. Becker Hewes sold 729 shares of the company’s stock in a transaction dated Wednesday, December 15th. The shares were sold at an average price of $100.00, for a total transaction of $72,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,729 shares of company stock valued at $657,700. Insiders own 3.34% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Blueprint Medicines by 2.7% in the 4th quarter. BlackRock Inc. now owns 5,336,874 shares of the biotechnology company’s stock valued at $571,632,000 after purchasing an additional 138,860 shares during the period. William Blair Investment Management LLC grew its stake in Blueprint Medicines by 1.8% in the 4th quarter. William Blair Investment Management LLC now owns 1,747,721 shares of the biotechnology company’s stock valued at $187,198,000 after buying an additional 30,557 shares during the last quarter. EFG Asset Management North America Corp. acquired a new position in Blueprint Medicines in the 4th quarter valued at about $12,082,000. California State Teachers Retirement System grew its stake in Blueprint Medicines by 2.5% in the 4th quarter. California State Teachers Retirement System now owns 78,978 shares of the biotechnology company’s stock valued at $8,459,000 after buying an additional 1,953 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in Blueprint Medicines by 14.2% in the 4th quarter. Parametric Portfolio Associates LLC now owns 70,229 shares of the biotechnology company’s stock valued at $7,522,000 after buying an additional 8,720 shares during the last quarter.

Blueprint Medicines Company Profile (Get Rating)

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Featured Articles

  • Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
  • MarketBeat: Week in Review 2/21 – 2/25
  • Volatility Spikes On Russian Aggression In Ukraine 
  • Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
  • The Facts are Supporting the Justified Enthusiasm for Teladoc Health
  • It’s Time To Snack On Ruth’s Hospitality Group 

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Blueprint Medicines right now?

Before you consider Blueprint Medicines, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Blueprint Medicines wasn’t on the list.

While Blueprint Medicines currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT